← All trials
NCT04721691
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Jan 25, 2021
- Last posted
- Jul 16, 2021
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Northwell HealthLead sponsor
- Northwell HealthReponsible party - principal investigator
- Greenwich BiosciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.